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Introduction  
Liver transplantation is an overall success story and has led worldwide to much more 
candidates on waiting lists than donor organs available
1-2
. This discrepancy between liver 
supply and demand has forced professionals to consider grafts from so-called extended 
criteria donors (ECD). Such livers induce, however, for more post-transplant complications, 
including primary-non-function (PNF), early allograft dysfunction (EAD), biliary 
complications and graft loss
3-5
. Key factors for liver graft dysfunction include donor warm 
ischemia (donation after circulatory arrest, DCD), graft steatosis, and prolonged conventional 
cold storage of more than 10 hrs
1,2,6
. Graft optimization or repair strategies before 
implantation are therefore of high importance to improve outcome. This presentation focus 
on underlying mechanisms of injury throughout procurement and implantation with special 
emphasis on hypothermic machine perfusion. 
1. Injury during procurement and implantation 
Liver injury already starts before organ procurement, e.g. during brain death (DBD), 
or due to donor warm ischemia in donation after cardiac death (DCD).  After such initial 
injury already in donors, liver grafts undergo the process of retrieval surgery, including cold 
flush and cold storage. While cooling is a well-established procedure to slow down energy 
demand, a number of negative effects have been reported, e.g. depletion of adenine 
nucleotide pool
7
, lactate acidosis
8
, increase of chelatable iron
9
, intracellular calcium 
accumulation
10
, calpain activation
11,12
 and sinusoidal endothelial damage
13
. All these effects 
are triggered by  anaerobic metabolism, and limit therefore the maximum time period for cold 
storage due to  deleterious effects on plasma membrane lipids, cytoskeleton, microtubules, 
and mitochondria, disabling the ion-exchange pumps and consequently membrane swelling 
and cell lysis
14
. 
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During implantation, liver grafts are further exposed to ischemic rewarming, once more 
aggravating anaerobic metabolism. Subsequently, a re-exposure with normothermic blood 
and oxygen during implantation triggers an immediate burst of reactive oxygen species 
within the first minutes of reperfusion
15
. The mechanism behind has been shown to be 
dependent on mitochondrial derived injury
16
, caused by mitochondrial electron leaksmainly 
due to reverse electron flow from mitochondrial complex II to complex I (RET)
17
. 
Thiscorrelates with massive oxidative injury of mitochondrial membranes and also DNA
18
 
and results in downstream release of danger associated molecular patterns (DAMPs)
19
, 
activating of toll-like-receptors (TLR) located on non-parenchymal liver cells, and in release 
of numerous inflammatory mediators (Figure 1)
20
. Any efforts to restore blood flow in 
hypoxic tissue, therefore, paradoxically induce potentially more destructive than beneficial 
effects, depending on the amount of accumulated injury during the ischemic period
21
.  
2. Hypothermic perfusion concept 
 
2.1. Idea and Mechanism 
The current data point to the fact that oxygenation of the mitochondrial electron chain 
under hypothermic conditions, e.g. hypothermic oxygenated perfusion (HOPE), is the key 
element for the protection of hypothermic machine perfusion against reperfusion injury
22
. 
Three effects emerge due to this. First, function of mitochondrial enzyme complexes is 
improved during cold oxygenated perfusion, probably leading to forward instead of reverse 
electron flow. Secondly, adenine nucleotides are significantly uploaded to high levels during 
cold oxygenation, consecutively to a “repair” of mitochondrial function
23
. Third, the cellular 
redox state changes from reduced to oxidized
23
. Treatment by HOPE results therefore in less 
oxidative injury, less release of DAMPs, less activation of toll like receptors and improved 
liver function upon implantation. This effect is similar for DCD and steatotic liver grafts
24,25
. 
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Furthermore, HOPE is not only effective against reperfusion injury but prevents also down-
stream activation of immune response pathways
26
.  
One of the major advantages of hypothermic machine perfusion is its easy 
applicability, e.g. an endischemic approach after initial cold storage is effective. Thus, 
machine perfusion under cold conditions does not necessarily need to start at the place of 
organ donation
25
.  Furthermore, HOPE perfusion was equally protective in DCD kidneys in a 
rodent model of kidney transplantation
27
. 
2.2. Clinical Data 
Hypothermic dual (portal vein and hepatic artery) perfusion of the first twenty 
standard DBD human livers has been reported 2010 by Guarerra et al
28
. Machine perfusion 
was applied without additional active oxygenation after previous cold storage and transport of 
organs to the perfusion center. Of note, despite the lack of oxygenators in the circuit, the 
perfusate pO2 was sufficient in enabling aerobic conditions during perfusion
28
. The results 
showed, that perfusion resulted in significantly less peak enzyme release and shorter hospital 
stay, as well as less early graft dysfunction compared to a non-randomized control group
28
. In 
a further report, the same investigators recently showed less biliary complication after 
application of hypothermic perfusion to marginal DBD organs
29
. Consistent to these results, 
hypothermic perfusion including active oxygenation (HOPE) has been shown by our group to 
be protective in human extended DCD liver grafts, despite very long donor warm ischemia 
times
30
, with no occurrence of intrahepatic biliary complications in contrast to matched un-
perfused DCD livers
31
. Importantly, HOPE treatment appeared sufficient by single portal 
vein perfusion, as the entire intra- and extrahepatic biliary system is positively effected 
through multiple collaterals between portal vein and hepatic artery
32,33
. Randomized trials are 
Page 5 of 12
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
6 
 
therefore initiated to further evaluate the effect of HOPE on DBD and DCD liver grafts 
(hope-liver.com - Zurich, Groningen Institute for Organ transplantation - GIOT)
34
.  
Of note, a hypothermic oxygenated perfusion approach was tested recently in 
Maastricht Type II DCD livers following normothermic regional perfusion (NRP), or after 
extended cold storage
35
. In addition, the first long-term outcome analysis of HOPE treated 
DCD livers has been completed, showing excellent 5-year graft survival comparable to DBD 
liver transplantations
36
. 
2.3. Viability Assessment 
Similarly, to liver enzyme measurements during normothermic perfusion, detection of 
several parameters during HMP and HOPE is currently under evaluation, e.g. microRNA
37
, 
DAMP release
38
, citric acid metabolites
39
, parameters of mitochondrial function
40
, and 
nucleotid pool assessment
41
.  Several of these compounds may correlate to liver function after 
transplantation, but remain to be further investigated. 
2.4. Future Aspects 
 
Hypothermic perfusion is currently applied end-ischemically, after initial cold flush 
and storage. Whether liver grafts can be again cold stored after short term HOPE treatment is 
currently under investigation. Graft optimization in perfusion centers, with afterwards cold 
storage transport to implantation centers, could help to provide more livers for more 
transplant centers that do not have access to machine perfusion yet.  
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3. Conclusion 
 
Repair of injured liver grafts and prediction of organ function before implantation are 
the two major concerns to allow the safe use of organs that were previously regarded as 
unsuitable. Much effort should therefore be directed to further developments of dynamic 
preservation methods, which will likewise replace static cold storage in high-risk grafts. In 
this context, reliable thresholds need to be defined for the difficult decision, which graft will 
benefit from machine perfusion treatment to provide a lifesaving, but also affordable 
optimization. More research and international concepts are necessary to further improve ex 
vivo medical treatment before transplantation, for example by new perfusion devices, e.g. 
Transmedics machine for normothermic perfusion, or Airdrive for hypothermic 
perfusion
42
, which will be compared to existing techniques. Highly attractive are, however, 
relative short perfusion and centre bound treatments of liver grafts before implantation, which 
can provide significantly uploads in cellular energy stores.  In all perfusion technologies, 
modern analytical technologies (e.g. proteomics, metabolomics) will be tested on liver tissue 
and perfusate, and may help to search for new biomarkers assessing graft quality before 
implantation.   
 
 
Table 1: Current clinical liver perfusion systems for hypothermic perfusion  
 
 
 
Company Pump Oxgenation Temperatur
e
Perfusion 
route
cost Transportation
Liver assist Organ Assist Centrifugal 
pump
Yes 10-37 °C single or dual 3500.-€ per 
disposable
in the OR
Airdrive QRS 
international
Membrane 
pump
Yes 8-12°C single or dual single use whole 
system
car or plane carriage
Life port liver 
transporter
Organ recovery Roller pump Yes 4-10 °C dual not specified car or plane carriage
Page 7 of 12
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
8 
 
 
4. References 
 
1.  Graham JA, Guarrera J V. “resuscitation” of marginal liver allografts for transplantation with 
machine perfusion technology. J Hepatol. 2014;61(2):418–31.  
2.  Jiménez-Romero C, Caso Maestro O, Cambra Molero F, Justo Alonso I, Alegre Torrado C, 
Manrique Municio A, et al. Using old liver grafts for liver transplantation: Where are the 
limits? Vol. 20, World Journal of Gastroenterology. 2014. p. 10691–702.  
3.  Dutkowski P, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, Mullhaupt B, et al. Are 
there better guidelines for allocation in liver transplantation? A novel score targeting justice 
and utility in the model for end-stage liver disease era. Ann Surg. 2011;254(5):745–53; 
discussion 753.  
4.  Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a 
current definition of early allograft dysfunction in liver transplant recipients and analysis of 
risk factors. Liver Transplant. 2010;16(8):943–9.  
5.  Jay C, Ladner D, Wang E, Lyuksemburg V, Kang R, Chang Y, et al. A comprehensive risk 
assessment of mortality following donation after cardiac death liver transplant - An analysis of 
the national registry. J Hepatol. 2011;55(4):808–13.  
6.  Merion RM, Goodrich NP, Feng S. How can we define expanded criteria for liver donors? J 
Hepatol 2006,45:484-488. 
7.  van Golen RF, Reiniers MJ, van Gulik TM, Heger M. Organ cooling in liver transplantation 
and resection: How low should we go? Vol. 61, Hepatology. 2015. p. 395–9.  
8.  Dutkowski P, Krug A, Krysiak M, Dünschede F, Seifert JK, Junginger T. Detection of 
mitochondrial electron chain carrier redox status by transhepatic light intensity during rat liver 
reperfusion. Cryobiology. 2003;47(2):125–42.  
9.  Petrat F, de Groot H, Sustmann R, Rauen U. The chelatable iron pool in living cells: A 
methodically defined quantity. Vol. 383, Biological Chemistry. 2002. p. 489–502.  
10.  Chang WJ, Chehab M, Kink S, Toledo-Pereyra LH. Intracellular calcium signaling pathways 
during liver ischemia and reperfusion. J Invest Surg. 2010;23(4):228–38.  
11.  Kohli V, Gao W, Camargo, JR. C a., Clavien PA. Calpain is a mediator of preservation-
reperfusion injury in rat liver transplantation. Proc Natl Acad Sci USA. 1997;94(3247):9354–
9.  
12.  Chen M, Won DJ, Krajewski S, Gottlieb RA. Calpain and mitochondria in 
ischemia/reperfusion injury. J Biol Chem. 2002;277(32):29181–6.  
13.  Malhi H, Gores GJ. Cellular and Molecular Mechanisms of Liver Injury. Gastroenterology. 
2008;134(6):1641–54.  
14.  Takakuwa Y, Nishino H, Ishibe Y, Ishibashi T. Properties and kinetics of membrane-bound 
enzymes when both the enzyme and substrate are components of the same microsomal 
membrane. Studies on lathosterol 5-desaturase. J Biol Chem. 1994;269(45):27889–93.  
15.  Van Golen RF, Van Gulik TM, Heger M. Mechanistic overview of reactive species-induced 
degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury. Vol. 52, 
Free Radical Biology and Medicine. 2012. p. 1382–402.  
Page 8 of 12
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
9 
 
16.   Pryde KR, Hirst J. Superoxide is produced by the reduced flavin in mitochondrial complex I. J 
Biol Chem 2011, 18056-18065. 
17.      Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, et al. Ischaemic 
accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 
2014;515(V):431–5..  
18.  Jaeschke H. Reactive oxygen and mechanism of inflammatory liver injury: Present concepts. J 
Gatroenterol Hepatol 2011: 173-179. 
19.      Schlegel A, Graf R, Clavien PA, Dutkowski P. Hypothermic oxygenated perfusion (HOPE) 
protects from biliary injury in a rodent model of DCD liver transplantation. J Hepatol. 2013 
Nov;59(5):984–91.  
20.  Schlegel A, Kron P, Dutkowski P. Hypothermic machine perfusion in liver transplantation. 
Curr Opin Organ Transplant. 2016 Jun;21(3):308–14.  
21.  Blackstone C, Chang C-R. Mitochondria unite to survive. Nat Cell Biol. 2011;13(5):521–2.  
22.  Schlegel A, Rougemont O De, Graf R, Clavien PA, Dutkowski P. Protective mechanisms of 
end-ischemic cold machine perfusion in DCD liver grafts. J Hepatol. 2013 Feb;58(2):278–86. 
23. Dutkowski P, Graf R, Clavien PA. Rescue of the cold preserved rat liver by hypothermic 
oxygenated machine perfusion. Am J Transpl 2006: 903-912. 
24.      Schlegel A, Kron P, Graf R, Dutkowski P, Clavien PA. Warm vs. cold perfusion techniques to 
rescue rodent liver grafts. J Hepatol. 2014;61(6):1267–75. 
25.      Schlegel A, Dutkowski P. Role of hypothermic machine perfusion in liver transplantation. Vol. 
28, Transplant International. Blackwell Publishing Ltd; 2015. p. 677–89. 
26.      Schlegel A, Kron P, Graf R, Clavien P-A, Dutkowski P. Hypothermic Oxygenated Perfusion 
(HOPE) downregulates the immune response in a rat model of liver transplantation. Ann Surg. 
2014;260(5):931-7-8.  
27.      Kron P, Schlegel A, de Rougemont O, Oberkofler CE, Clavien P-A, Dutkowski P. Short, Cool, 
and Well Oxygenated - HOPE for Kidney Transplantation in a Rodent Model. Ann Surg. 
2016: 815-822. 
28.      Guarrera J V., Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, et al. 
Hypothermic machine preservation in human liver transplantation: The first clinical series. Am 
J Transplant. 2010;10(2):372–81.  
29.  Guarrera J V., Henry SD, Samstein B, Reznik E, Musat C, Lukose TI, et al. Hypothermic 
machine preservation facilitates successful transplantation of “orphan” extended criteria donor 
livers. Am J Transplant. 2015;15(1):161–9 
30.      Dutkowski P, Schlegel A, De Oliveira M, Müllhaupt B, Neff F, Clavien PA. HOPE for human 
liver grafts obtained from donors after cardiac death. J Hepatol. 2014;60(4):765–72..  
31.  Dutkowski P, Polak WG, Muiesan P, Schlegel A, Verhoeven CJ, Scalera I, et al. First 
Comparison of Hypothermic Oxygenated PErfusion Versus Static Cold Storage of Human 
Donation After Cardiac Death Liver Transplants: An International-matched Case Analysis. 
Ann Surg. 2015;262(5):764–71. 
32.      Schlegel A, Kron P, De Oliveira ML, Clavien PA, Dutkowski P. Reply to “Is single portal vein 
perfusion the best approach for machine preservation of liver grafts?” Vol. 64, Journal of 
Hepatology. 2016. p. 1195–6.  
33.  Schlegel A, Kron P, De Oliveira ML, Clavien PA, Dutkowski P. Is single portal vein approach 
sufficient for hypothermic machine perfusion of DCD liver grafts? Vol. 64, Journal of 
Page 9 of 12
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
10 
 
Hepatology. 2016. p. 239–41. 
34.      Jochmans I, Akhtar MZ, Nasralla D, Kocabayoglu P, Boffa C, Kaisar M, et al. Past, Present, 
and Future of Dynamic Kidney and Liver Preservation and Resuscitation. Am J Transplant. 
2016;16(9):2545–55.  
35.      De Carlis L, De Carlis R, Lauterio A, Di Sandro S, Ferla F, Zanierato M. Sequential use of 
normothermic Regional Perfusion and Hypothermic Machine Perfusion in Donation After 
Cardiac Death Liver Transplantation with Extended Warm Ischemia Time. Transplantation. 
2016; October; 10, p e 101-e102. 
36.      Schlegel A, Muller X, Perera T, Clavien P.-A, Isaac J, Muiesan P, Dutkowski P, 5-year 
experience in human extended DCD liver transplantation treated by hypothermic oxygenated 
perfusion (HOPE) before implantation, Abstract Congress International Liver Transplantation 
Society Prague, 2017.  
37.  Verhoeven CJ, Farid WRR, De Ruiter PE, Hansen BE, Roest HP, De Jonge J, et al. 
MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary 
lesions after liver transplantation. J Hepatol. 2013;59(6):1231–8.  
38.  Sutton ME, Op Den Dries S, Karimian N, Weeder PD, De Boer MT, Wiersema-Buist J, et al. 
Criteria for Viability Assessment of Discarded Human Donor Livers during Ex Vivo 
Normothermic Machine Perfusion. PLoS One. 2014;9(11).     
39.  Yarmush G, Santos L, Yarmush J, Koundinyan S, Saleem M, Nativ NI, et al. Metabolic Flux 
Distribution during Defatting of Steatotic Human Hepatoma (HepG2) Cells. Metabolites. 
2016;6(1):1.   
40.  Farid WRR, Verhoeven CJ, De Jonge J, Metselaar HJ, Kazemier G, Van Der Laan LJW. The 
ins and outs of microRNAs as biomarkers in liver disease and transplantation. Vol. 27, 
Transplant International. 2014. p. 1222–32.  
41.  Roedder S, Vitalone M, Khatri P, Sarwal MM. Biomarkers in solid organ transplantation: 
establishing personalized transplantation medicine. Genome Med. 2011;3(6):37 
42.       Compagnon P, Levesque E, Hentati H, Disabato M, Calderaro J, Feray C, Corlu A, Cohen JL, 
Ben Mosbah I, Azoulay D.  An Oxygenated and Transportable Machine Perfusion System 
Fully Rescues Liver Grafts Exposed to Lethal Ischemic Damage in a Pig Model of DCD Liver 
Transplantation. Transplantation 2017: e205-e213.   
  
 
 
 
    
 
 
 
 
 
 
Page 10 of 12
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
  
 
 
Mechanism of ischemia reperfusion injury  
 
254x190mm (300 x 300 DPI)  
 
 
Page 12 of 12
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
